VPCAT Project Sarah Majercik, MD, MBA, FACS 7 April 2017 Venous - - PowerPoint PPT Presentation

vpcat project
SMART_READER_LITE
LIVE PREVIEW

VPCAT Project Sarah Majercik, MD, MBA, FACS 7 April 2017 Venous - - PowerPoint PPT Presentation

VPCAT Project Sarah Majercik, MD, MBA, FACS 7 April 2017 Venous Thromboembolism Screening in the Trauma Population A Randomized Vanguard Trial VTE is a major problem after trauma In patients who survive >72 hours after traumatic


slide-1
SLIDE 1

VPCAT Project

Sarah Majercik, MD, MBA, FACS 7 April 2017

slide-2
SLIDE 2

Venous Thromboembolism Screening in the Trauma Population—A Randomized Vanguard Trial

slide-3
SLIDE 3

VTE is a major problem after trauma

  • In patients who survive

>72 hours after traumatic insult, VTE is a main cause

  • f death
  • Reported incidence in

trauma patients:

  • DVT 11.8%-65%
  • PE 1.5%-2.3%
  • IMC rate
  • DVT 3%
  • PE 0.6%
slide-4
SLIDE 4

Why is VTE an issue in trauma patients?

slide-5
SLIDE 5

Why is VTE an issue in trauma patients?

  • Traumatic injury causes direct or indirect endothelial

injury, activates tissue factor, platelet aggregation, propagating the coagulation cascade, e.g. TRAUMA

  • Trauma patients are often immobile and need surgical

procedures, e.g. STASIS

  • Acute phase reactants from trauma itself and from

postoperative state, e.g. HYPERCOAGULABILITY

slide-6
SLIDE 6
  • Venous Thromboembolism (VTE) is responsible for a $69billion

economic impact annually in the US

  • VTE is a major cause of late morbidity and mortality in trauma patients
  • At the time of VTE diagnosis, most patients are already receiving

standard chemoprophylaxis

  • VTE will never be a “never” event in trauma, no matter what CMS

would like to tell us—it is on the HAC score checklist

Background

slide-7
SLIDE 7

Background

Therapy guidelines just published in 2016

slide-8
SLIDE 8

Most Recent Prevention Guidelines are from 2012

Background

slide-9
SLIDE 9

Routine surveillance NOT recommended!

Current recommendation for major trauma patients is NO surveillance

slide-10
SLIDE 10
slide-11
SLIDE 11

VTE surveillance in trauma patients

  • Quality of evidence to support this recommendation is

poor

  • Mostly retrospective
  • Often conflicting
slide-12
SLIDE 12

Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr;38(4 Suppl):S502-9. Haut ER, Schneider EB, Patel A, Streiff MB, Haider AH, Stevens KA, Chang DC, Neal ML, Hoeft C, Nathens AB, Cornwell EE 3rd, Pronovost PJ, Efron DT. Duplex ultrasound screening for deep vein thrombosis in asymptomatic trauma patients: a survey of individual trauma surgeon opinions and current trauma center

  • practices. J Trauma. 2011 Jan;70(1):27-33.

Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. Antithrombotic Therapy and Prevention

  • f Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

CHEST 2012; 141(2)(Suppl):7S–47S. Adams RC, Hamrick M, Berenguer C, Senkowski C, Ochsner MG. Four Years of an Aggressive Prophylaxis and Screening Protocol for Venous Thromboembolism in a Large Trauma Population. J Trauma. 2008 Aug;65(2):300-6. Napolitano LM, Garlapati VS, Heard SO, Silva WE, Cutler BS, O’Neill AM, Anderson FA Jr, Wheeler HB. Asymptomatic deep venous thrombosis in the trauma patient: is an aggressive screening protocol justified? J Trauma. 1995 Oct;39(4):651-7. Malhotra AK, Goldberg SR, McLay L, Martin NR, Wolfe LG, Levy MM, Khiatani V, Borchers TC, Duane TM, Aboutanos MB, Ivatury RR. DVT Surveillance Program in the ICU: Analysis of Cost-Effectiveness. PLoS One. 2014 Sep 30;9(9):e106793 . doi: 10.1371/journal.pone.0106793. Cipolle MD, Wojcik R, Seislove E, Wasser TE, Pasquale MD. The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. J Trauma. 2002 Mar;52(3):453-62. Schwarcz TH, Quick RC, Minion DJ, Kearney PA, Kwolek CJ, Endean ED. Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning. J Vasc Surg. 2001 Sep;34(3):447- 52

Investigators are interested in this topic, but no one has successfully executed a good quality study!

slide-13
SLIDE 13
  • Based on this grade 2C (mostly retrospective) evidence,

most trauma centers in the United States choose not to perform surveillance on trauma patients

  • Intermountain Medical Center has traditionally performed

Duplex Ultrasound surveillance on high risk trauma patients

  • Consequently, our VTE rate (mostly asymptomatic DVT) is

higher than has been deemed “acceptable”

slide-14
SLIDE 14

There are currently ZERO prospective, randomized studies that specifically examine VTE surveillance in the trauma patient

slide-15
SLIDE 15

Why is this important?

  • Asymptomatic lower extremity DVT diagnosis is not really

the point—preventing fatal PE is.

  • Hospitals under pressure to decrease DVT rate
  • If we stop looking, our rate will decrease…
  • Is this the best patient care?
slide-16
SLIDE 16

HYPOTHESIS: High risk trauma patients who undergo scheduled ultrasound surveillance for lower extremity DVT will have a lower rate of:

  • Symptomatic DVT
  • DVT propagation
  • Symptomatic or fatal PE
slide-17
SLIDE 17

Specific Aims:

  • 1. Determine the rate of VTE (DVT and PE) in high-risk

trauma patients who have surveillance for lower extremity DVT versus those who do not have surveillance

  • 2. Determine the rate of DVT propagation to the popliteal

vein or higher by 14 days after discharge in high-risk trauma patients found to have isolated distal DVT

slide-18
SLIDE 18

Outcome Measures: 1. Asymptomatic lower extremity DVT identified during hospitalization (in surveillance group) 2. Symptomatic DVT identified during hospitalization and at 90 days post discharge 3. Symptomatic DVT propagation from calf to proximal veins at 14 days post-discharge 4. Symptomatic/fatal PE identified during hospitalization and at 90 days post-discharge 5. Major bleeding episodes 6. Composite outcome of proximal DVT plus major bleeding episodes 7. All cause mortality at 90 days post-discharge

slide-19
SLIDE 19

Study Design:

  • 1. Prospective, randomized trial—surveillance at days 1, 3, 7,

weekly vs. no surveillance

  • 2. Exception from informed consent approved by IRB
  • 3. All high risk trauma patients enrolled
slide-20
SLIDE 20

Inclusion Criteria:

  • 1. Inpatient on IMC trauma surgery service, admitted within

24 hours of injury

  • 2. Age ≥ 18
  • 3. Meets definition of high-risk for VTE
slide-21
SLIDE 21

Exclusion Criteria: 1. Age <18 2. Pregnancy 3. Prisoners 4. Life expectancy <30 days 5. Known hypercoagulable state, including Factor V Leiden, Protein C and S deficiencies, dysfibrogenemia, active cancer, antiphospholipid antibody syndrome

slide-22
SLIDE 22

Data Analysis:

  • Used historic baseline of

composite outcome of major bleeding plus proximal DVT on trauma service to conduct power analysis

slide-23
SLIDE 23

Current Status:

  • Enrolling patients
  • Estimate 12-16 months to complete enrollment
  • Relatively low ISS and homogeneous population of IMC trauma service will be

a limitation

slide-24
SLIDE 24

Future Plans

  • Results of this vanguard trial will pave the way for a larger,

likely multi-institutional trial

  • Will answer an important question that will impact trauma

patients everywhere—far beyond just Intermoutain